These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

89 related items for PubMed ID: 21141077

  • 1. [Long-acting carteolol hydrochloride 2% ophthalmic solution phase IV study--investigation of the effectiveness, safety and plasma concentration].
    Kawase K, Yamamoto T, Muramatsu T, Ono J, Nakajima T, Matsuhisa A, Sugiura T, Migita M, Ishikawa Y.
    Nippon Ganka Gakkai Zasshi; 2010 Nov; 114(11):976-82. PubMed ID: 21141077
    [Abstract] [Full Text] [Related]

  • 2. [Ocular hypotensive effect of 1% carteolol long-acting eye drops--a double-masked, randomized phase III study in ocular hypertension or primary open-angle glaucoma patients comparing long-acting carteolol eye drops vs. current product].
    Yamamoto T, Carteolol Long-acting Formulation Study Group.
    Nippon Ganka Gakkai Zasshi; 2007 Jun; 111(6):463-72. PubMed ID: 17601060
    [Abstract] [Full Text] [Related]

  • 3. [Efficacy and safety of long-acting carteolol 1% once daily. A double-masked, randomized study].
    Trinquand C, Romanet JP, Nordmann JP, Allaire C, Groupe d'étude.
    J Fr Ophtalmol; 2003 Feb; 26(2):131-6. PubMed ID: 12660585
    [Abstract] [Full Text] [Related]

  • 4. Cardiovascular effects of topical carteolol hydrochloride and timolol maleate in patients with ocular hypertension and primary open-angle glaucoma. Night Study Group.
    Netland PA, Weiss HS, Stewart WC, Cohen JS, Nussbaum LL.
    Am J Ophthalmol; 1997 Apr; 123(4):465-77. PubMed ID: 9124243
    [Abstract] [Full Text] [Related]

  • 5. Comparison of carteolol plasmatic levels after repeated instillations of long-acting and regular formulations of carteolol 2% in glaucoma patients.
    Renard P, Kovalski JL, Cochereau I, Jaulerry S, Williamson W, Elena PP, Lablache Combier M, Allaire C, Siou-Mermet R.
    Graefes Arch Clin Exp Ophthalmol; 2005 Dec; 243(12):1221-7. PubMed ID: 16003515
    [Abstract] [Full Text] [Related]

  • 6. Ocular hypotensive efficacy and safety of once daily carteolol alginate.
    Demailly P, Allaire C, Trinquand C, Once-daily Carteolol Study Group.
    Br J Ophthalmol; 2001 Aug; 85(8):921-4. PubMed ID: 11466245
    [Abstract] [Full Text] [Related]

  • 7. Effect of carteolol hydrochloride on 24-hour variation of intraocular pressure in normal-tension glaucoma.
    Nakamoto K, Yasuda N.
    Jpn J Ophthalmol; 2010 Mar; 54(2):140-3. PubMed ID: 20401563
    [Abstract] [Full Text] [Related]

  • 8. [Efficacy and tolerability of 2 presentations of eyedrops combining carteolol 2% and pilocarpine 2% in primary open-angle glaucoma and simple ocular hypertension].
    Sirbat D, Charlin JF, Cohn H, Dascotte JC, George JL, Lesure P, Massin M, Massin G, Maurin JF, Renard JP.
    J Fr Ophtalmol; 1995 Mar; 18(10):589-96. PubMed ID: 8568162
    [Abstract] [Full Text] [Related]

  • 9. Carteolol: preliminary study on ocular pressure-reducing action.
    Gorgone G, Spina F, Amantia L.
    Ophthalmologica; 1983 Mar; 187(3):171-3. PubMed ID: 6355953
    [Abstract] [Full Text] [Related]

  • 10. Effects of switching from topical beta-blockers to latanoprost on intraocular pressure in patients with normal-tension glaucoma.
    Ikeda Y, Mori K, Ishibashi T, Naruse S, Nakajima N, Kinoshita S.
    J Ocul Pharmacol Ther; 2008 Apr; 24(2):230-4. PubMed ID: 18341431
    [Abstract] [Full Text] [Related]

  • 11. Pharmacokinetic and pharmacodynamic differences between ocular and nasal instillation of carteolol on intraocular pressure and heart rate in Japanese men with high CYP2D6 activity.
    Ishii Y, Nakamura K, Matsuki S, Uemura N, Muraguchi R, Nakagawa M, Nakano S, Nakatsuka K.
    J Clin Pharmacol; 2002 Sep; 42(9):1020-6. PubMed ID: 12211218
    [Abstract] [Full Text] [Related]

  • 12. Additive effect of dorzolamide or carteolol to latanoprost in primary open-angle glaucoma: a prospective randomized crossover trial.
    Maruyama K, Shirato S.
    J Glaucoma; 2006 Aug; 15(4):341-5. PubMed ID: 16865013
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of timolol solution once daily versus timolol gel in treating elevated intraocular pressure.
    Stewart WC, Leland TM, Cate EA, Stewart JA.
    J Glaucoma; 1998 Dec; 7(6):402-7. PubMed ID: 9871862
    [Abstract] [Full Text] [Related]

  • 14. The safety and efficacy of travoprost 0.004%/timolol 0.5% fixed combination ophthalmic solution.
    Barnebey HS, Orengo-Nania S, Flowers BE, Samples J, Mallick S, Landry TA, Bergamini MV.
    Am J Ophthalmol; 2005 Jul; 140(1):1-7. PubMed ID: 15990081
    [Abstract] [Full Text] [Related]

  • 15. [Effect of 0.004% travoprost and 2% carteolol on intraocular pressure in patients with ocular hypertension after laser peripheral iridotomy or trabeculectomy in primary angle-closure glaucoma].
    Yao BQ, Pang YY, Li YX.
    Zhonghua Yan Ke Za Zhi; 2013 Apr; 49(4):340-4. PubMed ID: 23900094
    [Abstract] [Full Text] [Related]

  • 16. A comparison of the ocular hypotensive efficacy and systemic safety of 0.5% levobunolol and 2% carteolol.
    Behrens-Baumann W, Kimmich F, Walt JG, Lue J.
    Ophthalmologica; 1994 Apr; 208(1):32-6. PubMed ID: 8145982
    [Abstract] [Full Text] [Related]

  • 17. Effect of topical beta-blockers on tissue blood flow in the human optic nerve head.
    Tamaki Y, Araie M, Tomita K, Nagahara M, Tomidokoro A.
    Curr Eye Res; 1997 Nov; 16(11):1102-10. PubMed ID: 9395769
    [Abstract] [Full Text] [Related]

  • 18. [Comparative multicenter study of carteolol eyedrops with other beta blockers in 768 patients under normal conditions].
    Schnarr KD.
    Klin Monbl Augenheilkd; 1988 Feb; 192(2):167-72. PubMed ID: 2896266
    [Abstract] [Full Text] [Related]

  • 19. Patient preference, efficacy, and compliance with timolol maleate ophthalmic gel-forming solution versus timolol maleate ophthalmic solution in patients with ocular hypertension or open-angle glaucoma.
    Schenker H, Maloney S, Liss C, Gormley G, Hartenbaum D.
    Clin Ther; 1999 Jan; 21(1):138-47. PubMed ID: 10090431
    [Abstract] [Full Text] [Related]

  • 20. Serial administration of adrenergic antagonist and agonist ("pulsatile therapy") reduces the incidence of long-term drift to timolol in humans.
    Gandolfi SA, Vecchi M.
    Invest Ophthalmol Vis Sci; 1996 Mar; 37(4):684-8. PubMed ID: 8595970
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.